SCHEDULE: Gilde Healthcare Cuts LAVA Therapeutics Stake to 11.2%

Gilde Healthcare has significantly reduced its beneficial ownership in LAVA Therapeutics N.V. by selling over 2.2 million common shares in open market transactions.

Summary

• Gilde Healthcare, through its affiliated entities, sold an aggregate of 2,298,711 common shares of LAVA Therapeutics N.V.
• These sales occurred in open market transactions between October 14, 2025, and October 17, 2025.
• Following these sales, Gilde Healthcare's beneficial ownership stands at 2,947,781 common shares, representing approximately 11.2% of the outstanding shares.
• The total proceeds from these sales amounted to approximately $3,416,786.33.
• The shares were sold at weighted average prices ranging from $1.4743 to $1.5092 per share.

Sentiment

Score: 3

Explanation: The significant reduction in stake by a major institutional investor like Gilde Healthcare is generally viewed negatively by the market, suggesting a potential lack of confidence or a strategic exit from a portion of their investment. This could lead to downward pressure on the stock price and reduced investor sentiment.

Negatives

• A significant institutional investor, Gilde Healthcare, has substantially reduced its stake in LAVA Therapeutics N.V. by selling 2,298,711 common shares.
• The reduction in ownership from a major shareholder could signal a lack of confidence or a strategic shift by the investor.
• The sales occurred over several days, potentially adding selling pressure to the stock.

Risks

• The reduction in beneficial ownership by a significant institutional investor like Gilde Healthcare could be perceived negatively by the market, potentially leading to decreased investor confidence.
• Increased selling pressure on the stock due to the large volume of shares sold by Gilde Healthcare.
• Potential for further sales by Gilde Healthcare, although their current stake is 11.2%, which is still substantial.

Future Outlook

The filing does not contain any forward-looking statements or guidance from LAVA Therapeutics N.V. or Gilde Healthcare regarding the company's future performance or strategic direction.

Management Comments

• The filing includes signatures from Edwin de Graaf, Managing Director of Gilde Healthcare IV Management B.V., and Pieter van der Meer, Managing Director of Martemanshurk B.V., certifying the accuracy of the statement, but no direct commentary on the transaction's purpose or implications.

Industry Context

This filing primarily reflects a change in a significant investor's stake rather than broader industry trends. While institutional investor activity can influence market sentiment, the filing does not provide enough information to link Gilde Healthcare's divestment directly to specific shifts within the biotechnology or pharmaceutical sectors beyond their portfolio management decisions.

Comparison to Industry Standards

• The filing does not provide sufficient information to compare LAVA Therapeutics' performance or Gilde Healthcare's investment strategy against specific industry benchmarks or comparable companies. It focuses solely on the change in beneficial ownership.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential downward pressure on the stock price due to a major investor reducing its stake.
• Potential Investors: May view the reduction in institutional ownership as a cautionary signal, potentially impacting future investment decisions.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for LAVA Therapeutics N.V. or Gilde Healthcare beyond the reported share sales.

Key Dates

Recommendation

The substantial reduction in ownership by a significant institutional investor like Gilde Healthcare, selling over 2.2 million shares, typically signals a lack of conviction or a strategic divestment. This action can create negative market sentiment and selling pressure on the stock. While the remaining stake is still 11.2%, the trend of divestment from a major holder often precedes further declines or indicates underlying concerns not explicitly stated in the filing. Investors might consider selling to mitigate potential downside risk associated with this institutional exit.

Keywords

LAVA Therapeutics, Gilde Healthcare, Schedule 13D/A, Share Sales, Beneficial Ownership, Institutional Investor, Biotechnology, SEC Filing, Equity Stake